Terms: = Prostate cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Prognosis
274 results:
1. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of prostate cancer].
Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
[No Abstract] [Full Text] [Related]
2. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
[TBL] [Abstract] [Full Text] [Related]
3. Nadir prostate-specific antigen after salvage cryotherapy as a potential prognostic factor for oncologic outcomes.
Carbonell E; Mercader C; Sureda J; Gutiérrez A; Muñoz J; Gallardo E; Feltes N; Mases J; Valduvieco I; Vilaseca A; Franco A; Alcaraz A; Musquera M; Ribal MJ
World J Urol; 2024 Mar; 42(1):133. PubMed ID: 38478102
[TBL] [Abstract] [Full Text] [Related]
4. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
Guerrios-Rivera L; Janes JL; De Hoedt AM; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Fowke JH; Freedland SJ
Cancer Med; 2024 Feb; 13(4):e7012. PubMed ID: 38457188
[TBL] [Abstract] [Full Text] [Related]
5. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract] [Full Text] [Related]
6. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract] [Full Text] [Related]
7. Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study.
Murakami Y; Kawahara D; Soyano T; Kozuka T; Takahashi Y; Miyake K; Kashihara K; Kashihara T; Kamima T; Oguchi M; Murakami Y; Yoshioka Y; Nagata Y
Br J Radiol; 2024 Jan; 97(1153):142-149. PubMed ID: 38263831
[TBL] [Abstract] [Full Text] [Related]
8. The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ prostate cancer: A Multicenter Study.
Marra G; Rajwa P; Filippini C; Ploussard G; Montefusco G; Puche-Sanz I; Olivier J; Zattoni F; Moro FD; Magli A; Dariane C; Affentranger A; Grogg JB; Hermanns T; Chiu PK; Malkiewicz B; Kowalczyk K; Van den Bergh RCN; Shariat SF; Bianchi A; Antonelli A; Gallina S; Berchiche W; Sanchez-Salas R; Cathelineau X; Afferi L; Fankhauser CD; Mattei A; Karnes RJ; Scuderi S; Montorsi F; Briganti A; Deandreis D; Gontero P; Gandaglia G;
Clin Genitourin Cancer; 2024 Apr; 22(2):244-251. PubMed ID: 38155081
[TBL] [Abstract] [Full Text] [Related]
9. Risk of Biochemical Recurrence in Patients With Grade Group 1 prostate cancer With Extraprostatic Extension Treated With Radical prostatectomy.
Rezaee ME; Pallauf M; Fletcher SA; Han M; Pavlovich CP; Cornelia Ding CK; Epstein JI; Allaf ME; Trock BJ; Singla N
J Urol; 2024 Mar; 211(3):407-414. PubMed ID: 38109699
[TBL] [Abstract] [Full Text] [Related]
10. Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical prostatectomy.
Fukui Y; Yamada Y; Sakamoto S; Horikoshi T; Zhao X; Sato K; Nanba S; Kubota Y; Kanesaka M; Fujimoto A; Shibata H; Goto Y; Sazuka T; Imamura Y; Uno T; Ichikawa T
Anticancer Res; 2023 Dec; 43(12):5705-5712. PubMed ID: 38030183
[TBL] [Abstract] [Full Text] [Related]
11. Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics.
Zhang G; Zhang Z; Pei Y; Hu W; Xue Y; Ning R; Guo X; Sun Y; Zhang Q
Front Endocrinol (Lausanne); 2023; 14():1272806. PubMed ID: 38027108
[TBL] [Abstract] [Full Text] [Related]
12. Short-term prognosis of low-risk prostate cancer patients is favorable despite the presence of pathological prognostic factors: a retrospective study.
Semba R; Uchida K; Hirokawa Y; Shiraishi T; Onishi T; Sasaki T; Inoue T; Watanabe M
BMC Urol; 2023 Oct; 23(1):174. PubMed ID: 37904171
[TBL] [Abstract] [Full Text] [Related]
13. [Cuproptosis-related lncRNAs to predict biochemical recurrence of prostate cancer].
Zhao XD; Li Y; Wang ZH; Liu Z; Chen YH; Gu YF; Shang XJ; Xu S
Zhonghua Nan Ke Xue; 2023 Feb; 29(2):120-130. PubMed ID: 37847083
[TBL] [Abstract] [Full Text] [Related]
14. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
[TBL] [Abstract] [Full Text] [Related]
15. The Prognostic Significance of Selected HLA Alleles on prostate cancer Outcome.
Stokidis S; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833904
[TBL] [Abstract] [Full Text] [Related]
16. The prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in prostate cancer Treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract] [Full Text] [Related]
17. Therapeutic implications for localized prostate cancer by multiomics analyses of the ageing microenvironment landscape.
Gui C; Wei J; Mo C; Liang Y; Cen J; Chen Y; Wang D; Luo J
Int J Biol Sci; 2023; 19(12):3951-3969. PubMed ID: 37564213
[No Abstract] [Full Text] [Related]
18. 'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis.
Bogaard M; Skotheim RI; Maltau AV; Kidd SG; Lothe RA; Axcrona K; Axcrona U
Histopathology; 2023 Dec; 83(6):853-869. PubMed ID: 37501635
[TBL] [Abstract] [Full Text] [Related]
19. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract] [Full Text] [Related]
20. Tumor localization by prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy.
Fujimoto A; Sakamoto S; Horikoshi T; Zhao X; Yamada Y; Rii J; Takeuchi N; Imamura Y; Sazuka T; Matsusaka K; Ikeda JI; Ichikawa T
Sci Rep; 2023 Jun; 13(1):10079. PubMed ID: 37344491
[TBL] [Abstract] [Full Text] [Related]
[Next]
